A senior marketing director at Janssen Pharmaceuticals was questioned on the company’s promotion of the antipsychotic Risperdal as well as Janssen’s knowledge of the drug’s off-label use by children.
In Cirba v. Janssen Pharmaceuticals onWednesday, the second case in the Philadelphia Risperdal mass tort to go to trial, plaintiff William Cirba’s attorney, Thomas R. Kline of Kline & Specter, called Carmen DeLoria of Janssen’s global marketing division to the stand to discuss Risperdal and its place in the child and adolescent drug market.
